# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Buy to Hold.
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing n...